Oaktree Acquisition Corp. III Life Sciences
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
OACC$10.70-0.2%Stored close · as of Nov 5, 2026
Contents
Statement of Changes in Shareholders’ Deficit
| Class A · Class B · Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Ordinary Shares · Ordinary Shares · Paid-in · Accumulated · Shareholders’ | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | |
| Balance – June 28, 2024 (inception) | — | $— | — | $— | $— | $— | $— |
| Issuance of Class B ordinary shares to Sponsor | — | — | 5,031,250 | 503 | 24,497 | — | 25,000 |
| Sale of 550,000 private placement units | 583,981 | 58 | — | — | 5,839,752 | — | 5,839,810 |
| FV of Public Warrants at issuance | — | — | — | — | 215,029 | — | 215,029 |
| Forfeiture of Founder Shares | — | — | (231,493) | (23) | 23 | — | — |
| Allocated value of transaction costs to Class A shares | — | — | — | — | (48,996) | — | (48,996) |
| Accretion for Class A ordinary shares subject to redemption amount | — | — | — | — | (6,030,305) | (7,406,716) | (13,437,021) |
| Net income | — | — | — | — | — | 1,331,707 | 1,331,707 |
| Balance – December 31, 2024 | 583,981 | $58 | 4,799,758 | $480 | $— | $(6,075,009) | $(6,074,471) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.